Congress pondering biotech generics

07/5/2007 | Red Herring

The biotech industry sees some hope in a compromise bill to clarify the process for FDA approval of follow-on versions of biotech drugs that would allow 12 years of market exclusivity, but many biotech industry experts are concerned about the safety of potential follow-on biologics. Generic drugmakers in India and elsewhere are watching the legislation closely in hopes of entering the U.S. biogenerics market.

View Full Article in:

Red Herring

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC